IRIS Institutional Research Information System - OPENBS Open Archive UniBS

BELLUCCI, ARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.595
EU - Europa 4.409
AS - Asia 3.810
SA - Sud America 633
AF - Africa 93
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 5
Totale 15.557
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.475
PL - Polonia 1.628
SG - Singapore 1.275
CN - Cina 1.249
IT - Italia 623
UA - Ucraina 571
BR - Brasile 532
DE - Germania 437
HK - Hong Kong 401
VN - Vietnam 300
FI - Finlandia 272
FR - Francia 219
GB - Regno Unito 196
RU - Federazione Russa 130
IN - India 126
TR - Turchia 126
IE - Irlanda 110
BD - Bangladesh 96
CA - Canada 61
MX - Messico 37
NL - Olanda 35
ID - Indonesia 34
IQ - Iraq 34
SE - Svezia 34
AR - Argentina 32
KR - Corea 30
ZA - Sudafrica 27
BE - Belgio 26
CZ - Repubblica Ceca 26
JP - Giappone 24
ES - Italia 21
AT - Austria 17
PK - Pakistan 17
EC - Ecuador 15
VE - Venezuela 14
IL - Israele 12
KE - Kenya 12
UZ - Uzbekistan 12
AU - Australia 11
CO - Colombia 11
CH - Svizzera 10
JO - Giordania 10
AZ - Azerbaigian 9
EG - Egitto 9
MA - Marocco 9
NG - Nigeria 9
PY - Paraguay 9
PE - Perù 7
SK - Slovacchia (Repubblica Slovacca) 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
IR - Iran 6
LT - Lituania 6
BY - Bielorussia 5
CL - Cile 5
DZ - Algeria 5
ET - Etiopia 5
EU - Europa 5
GT - Guatemala 5
PT - Portogallo 5
HN - Honduras 4
KZ - Kazakistan 4
SA - Arabia Saudita 4
UY - Uruguay 4
AM - Armenia 3
BO - Bolivia 3
CR - Costa Rica 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
EE - Estonia 3
GR - Grecia 3
HU - Ungheria 3
JM - Giamaica 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
MU - Mauritius 3
MY - Malesia 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
RO - Romania 3
CY - Cipro 2
HR - Croazia 2
KG - Kirghizistan 2
LB - Libano 2
PA - Panama 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CM - Camerun 1
GE - Georgia 1
GY - Guiana 1
KW - Kuwait 1
LK - Sri Lanka 1
Totale 15.545
Salva come PNG Salva come JPEG
Città #
Warsaw 1.623
Singapore 695
Ashburn 586
Fairfield 561
Woodbridge 427
Jacksonville 421
Hong Kong 400
San Jose 296
Chandler 292
Dearborn 270
Beijing 266
Houston 251
Cambridge 245
Seattle 226
Brescia 223
The Dalles 220
Ann Arbor 207
Wilmington 201
Princeton 192
Helsinki 180
New York 171
Nanjing 145
Los Angeles 115
Dublin 109
Lauterbourg 100
Munich 100
Istanbul 94
Council Bluffs 92
Ho Chi Minh City 83
Milan 72
Dong Ket 66
Dallas 65
Des Moines 58
São Paulo 57
Buffalo 52
Jinan 50
San Francisco 50
Moscow 48
Nanchang 48
Santa Clara 46
Shanghai 46
Hanoi 45
Changsha 43
Chicago 43
Hebei 40
Shenyang 39
Pune 38
Orem 36
Tianjin 34
Boardman 32
Redondo Beach 31
San Diego 31
Denver 29
London 29
Jakarta 27
Turku 27
Brussels 25
Frankfurt am Main 25
Kunming 23
Phoenix 23
Toronto 23
Rome 22
Tokyo 22
Atlanta 20
Rio de Janeiro 20
Hangzhou 19
Brno 18
Guangzhou 18
Jiaxing 18
Nuremberg 18
Ningbo 17
Poplar 16
Taizhou 16
Brooklyn 15
Lappeenranta 15
Stockholm 14
Tucson 14
Zhengzhou 14
Ankara 13
Baghdad 13
Montreal 13
San Giuliano Milanese 13
Boston 12
Haiphong 12
Johannesburg 12
Manchester 12
Nairobi 12
Tashkent 12
Verona 12
Belo Horizonte 11
Dhaka 11
Hefei 11
Lanzhou 11
Mexico City 11
Norwalk 11
Amman 10
Amsterdam 10
Brasília 10
Lancaster 10
Paris 10
Totale 10.640
Salva come PNG Salva come JPEG
Nome #
Anionic liposomes for siRNA delivery to primary neuronal cells: evaluation of Alpha synuclein knockdown efficacy 376
Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation 365
Redistribution of DAT/α-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice modelling early Parkinson’s disease 314
Dopamine transporter/α-synuclein complexes are altered in the post mortem caudate putamen of Parkinson’s disease: An in situ proximity ligation assay study 306
NF-κB in Innate Neuroprotection and Age-Related Neurodegenerative Diseases 287
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. 278
INDUCTION OF INFLAMMATORY MEDIATORS AND MICROGLIAL ACTIVATION IN MICE TRANSGENIC FOR MUTANT P301S TAU PROTEIN 271
Mild inflammatory profile without gliosis in the c-rel deficient mouse modeling a late-onset parkinsonism 270
The End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging 264
The Contribution of -Synuclein Spreading to Parkinson’s Disease Synaptopathy 263
The "in situ" proximity ligation assay to probe protein-protein interactions in intact tissues 227
Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure 224
null 222
Alpha-Synuclein Preserves Mitochondrial Fusion and Function in Neuronal Cells 220
Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate 219
Mitochondria and alpha-synuclein: Friends or foes in the pathogenesis of Parkinson's disease? 210
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains 208
NF-κB/c-Rel deficiency causes Parkinson's disease-like prodromal symptoms and progressive pathology in mice 205
c-Rel deficient mice, a mouse model of "spreading" PD-like pathology. 197
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines 195
Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation 192
The proximity ligation assay: an high throughput technique for protein analysis in neuroscience 183
α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons 177
Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons 174
From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease 172
c-Rel deficient mice, a mouse model of “spreading” PD-like pathology 170
Synapsin III alterations in Parkinson's disease 166
Point mutated Caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature 164
Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases 164
Mitochondrial Dysfunction and Alpha-Synuclein Synaptic Pathology in Parkinson’s Disease: Who’s on First? 163
ALPHA-SYNUCLEIN MODULATES SYNAPSIN III IN NIGROSTRIATAL DOPAMINERGIC NEURONS: IMPLICATIONS FOR PARKINSON'S DISEASE 159
Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy 159
DIFFERENTIAL ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE SIGNALLING PATHWAYS IN THE HIPPOCAMPUS OF CRND8 TRANSGENIC MOUSE, A MODEL OF ALZHEIMER'S DISEASE 158
EFFECT OF SUBCHRONIC ADMINISTRATION OF METRIFONATE, RIVASTIGMINE AND DONEPEZIL ON BRAIN ACETYLCHOLINE IN AGED F344 RATS 155
Involvement of Synapsin III in the onset of alpha-synuclein synaptic pathology in Parkinson’s disease 153
Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer 153
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of Parkinson’s disease and dementia with Lewy bodies, 147
Design and Synthesis of Fluorescent Methylphenidate Analogues for a FRET-Based Assay of Synapsin III Binding 147
PGRN gene silencing in primary neuronal cultures: a model of FTLD-U 144
Synapsin III Alteration in Parkinson's disease 143
Involvement of Synapsin III in the onset of Alpha-synuclein pathology in Parkinson’s Disease 141
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. 140
AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons of Synapsin III knockout mice reveals novel molecular features involved in Parkinson's disease pathology. 140
ABNORMAL PROCESSING OF TAU IN THE BRAIN OF AGED TGCRND8 MICE 139
Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson’s Disease 138
ANALOGHI STRUTTURALI DEL METILFENIDATO COME AGENTI DISEASE-MODIFYING DELLA MALATTIA DI PARKINSON 138
Synapsin III Alteration in Parkinson's disease 137
Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives 136
Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation. 135
COMBINED TREATMENT WITH ATORVASTATIN AND MINOCYCLINE SUPPRESSES SEVERITY OF EAE 134
Alpha-synuclein and NMDA receptors: a novel postsynaptic couple playing a pivotal role in the regulation of the functional activity of nigral dopaminergic neurons 134
Alpha-synuclein modulates the localization, expression and function of NR2B-containing NMDA receptors: implications in the pathogenesis of Parkinson's disease 133
Exploring LRRK2-dependent clearance of α-synuclein pffs in glial cells via clusterin 129
Alpha-synuclein aggregation in dopaminergic cells is modulated by glucose metabolism 128
Role of dopamine D3R and acetylcholine nicotinic receptor interaction in the regulation of dopaminergic neurons function. 128
Extracellular clusterin limits the uptake of α-synuclein fibrils by murine and human astrocytes 128
An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders 128
Synapsin III and Alpha-Synuclein cooperation in the onset of synaptic pathology in Parkinson’s Disease 127
NF-κB unbalance and dysfunction in acute and age-related neurodegenerative disease 127
Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson’s disease 124
Synapsin III knock-out reduces AAV-alpha-synuclein overexpression-related neuropathology in the nigrostriatal system 122
The good and bad of therapeutic strategies that directly target α-synuclein 120
CHOLINERGIC DYSFUNCTION, NEURONAL DAMAGE AND AXONAL LOSS IN TGCRND8 MICE 118
Role of dopamine D3R/nAChR heterodimeric complex in the regulation of dopaminergic neurons function. 118
A novel stable transgenic zebrafish line expressing mCherry-tagged human alpha-synuclein in the nervous system and exhibiting all the key features of Lewy body disorders at larval stage 117
Parkinson's disease: from synaptic loss to connectome dysfunction 115
Study of alpha-synuclein fibrillation: State of the art and expectations 113
. Alpha-synuclein is a crucial mediator of mitochondrial fusion and functions 112
MicroRNA‑34a‑5p expression in the plasma and its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study 111
NF-κB/c-Rel DNA-binding is reduced in substantia nigra and peripheral blood mononuclear cells of Parkinson's disease patients 107
Selective dopaminergic alpha-synuclein pathological changes following glucose deprivation "in vitro": implications for Parkinson's disease 107
Neuroprotective epi-drugs quench the inflammatory response and microglial/macrophage activation in a mouse model of permanent brain ischemia 107
Effects of rofecoxib treatment on brain inflammatory reaction and cholinergic function in beta-(1-42) injected rats into the nucleus basalis 104
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson’s disease 102
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease 101
Non-steroid antiinflammatory agents (nsaids): are they a valid approach to Alzheimer’s disease prevention? 100
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and synaptic protein’s redistribution 99
Alpha-Synuclein is Involved in DYT1 Dystonia Striatal Synaptic Dysfunction 98
BETA-AMYLOID INFLAMMATION AND CHOLINERGIC HYPOFUNCTION IN THE RAT BRAIN IN VIVO: INVOLVEMENT OF P38MAPK PATHWAY 97
Alpha-synuclein absence affected mitochondrial fusion and functions 96
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy? 95
Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice 95
Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. 95
Redistribution of DAT/alpha-synuclein complexes visualized "in situ" by proximity ligation assay in a transgenic mouse model of Parkinson's disease 94
The contribution of β-amyloid, Tau and α-synuclein to blood–brain barrier damage in neurodegenerative disorders 93
In vivo effects of NSAIDs on amyloid beta(1-42)-induced brain neurotoxicity 92
THE SELECTIVE CYCLOOXIGENASE-2 INHIBITOR ROFECOXIB SUPPRESSES BRAIN INFLAMMATION AND PROTECTS CHOLINERGIC NEURONS FROM EXCITOTOXIC DEGENERATION IN VIVO 90
Ex vivo characterization of progranulin gene silencing in primary neuronal cultures to study the biological basis of FTLD-U 89
Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease 88
NSAIDs in Animal Models of Alzheimer's disease 88
Targeting α-Synuclein-Related Synaptic Pathology: Novel Clues for Parkinson’s Disease Therapy 86
Effects of novel NSAIDs on brain inflammation and release of neurotrasmitters in animal models of neurodegeneration 86
Neuroprotective effects of D2/D3 agonists in an "in vitro" model of dopaminergic degeneration 85
Novel perspectives for Parkinson’s disease therapy: insights from the latest advances in disease pathophysiology, diagnostic and experimental tools and molecular targets 84
NSAIDs in animal models of Alzheimer’s Disease 84
Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson's Disease 83
Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype 83
Early α-synuclein/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease 82
EXPERIMENTAL BRAIN INFLAMMATION AND NEURODEGENERATION AS MODEL OF ALZHEIMER'S DISEASE: PROTECTIVE EFFECTS OF SELECTIVE COX-2 INHIBITORS 82
Validation of synapsin III as a therapeutic target for Parkinson’s disease in the AAV-mediated alpha-synuclein mouse model 82
Totale 14.948
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.858
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.858
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021113 0 0 0 0 0 0 0 0 0 0 0 113
2021/2022810 49 153 31 32 9 46 33 62 34 80 92 189
2022/2023866 125 10 30 63 90 212 7 99 132 21 39 38
2023/2024967 63 20 91 60 57 177 46 50 185 20 32 166
2024/20252.168 15 36 35 257 238 156 231 103 247 158 395 297
2025/20264.493 393 511 307 689 495 398 693 168 237 364 193 45
Totale 15.942